Comparison of the cardiac electrophysiology and general toxicology of two formulations of intravenous amiodarone in dogs

Cardiovascular Toxicology

Volumn 9, Issue 3, 2009, Pages 126-133

  Cushing, Daniel J ^a   Cooper, Warren D ^a   Gralinski, Michael R ^b   Lipicky, Raymond J ^c   Kudenchuk, Peter J ^d   Kowey, Peter R ^a  

^a Prism Pharmaceuticals Inc   (United States)

^b CorDynamics Inc ^*  (United States)

^c School of Medicine ^*

^d LANKENAU HOSPITAL   (United States)

Author keywords

Amiodarone; Cardiac electrophysiology; Cyclodextrin; Toxicology

Indexed keywords

AMIODARONE; PLACEBO; PM 101; UNCLASSIFIED DRUG;

ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASYSTOLE; ATRIOVENTRICULAR CONDUCTION; BODY WEIGHT; BRADYCARDIA; CARDIOTOXICITY; COMPARATIVE STUDY; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE SEVERITY; DOG; DOSE RESPONSE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; ELECTROCARDIOGRAM; FEMALE; HEART ELECTROPHYSIOLOGY; HEART MUSCLE REFRACTORY PERIOD; HISTOPATHOLOGY; LOADING DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; CHEMICALLY INDUCED DISORDER; CHEMISTRY; EDEMA; HEART FUNCTION TEST; HYPERKINESIA; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; TIME;

ANIMALIA; CANIS FAMILIARIS;

AMIODARONE; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DOGS; EDEMA; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; FEMALE; HYPERKINESIS; INFUSIONS, INTRAVENOUS; MALE; TIME FACTORS;

EID: 70350428520     PISSN: 15307905     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12012-009-9044-4     Document Type: Article

References (16)

1. Helmy, I., Herre, J. M., Gee, G., Sharkey, H., Malone, P., Sauve, M. J., et al. (1988). Use of intravenous amiodarone for emergency treatment of life-threatening ventricular arrhythmias. Journal of the American College of Cardiology, 12, 1015-1022.
2. Scheinman, M. M., Levine, J. H., Cannom, D. S., Friehling, T., Kopelman, H. A., Chilson, D. A., et al. (1995). Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. The Intravenous Amiodarone Multicenter Investigators Group. Circulation, 92, 3264-3272.
3. Desai, A. D., Chun, S., & Sung, R. J. (1997). The role of intravenous amiodarone in the management of cardiac arrhythmias. Annals of Internal Medicine, 127, 294-303.
4. Kudenchuk, P. J. (1999). Intravenous antiarrhythmic drug therapy in the resuscitation from refractory ventricular arrhythmias. American Journal of Cardiology, 84, 52R-55R.
5. Cybulski, J., Kulakowski, P., Makowska, E., Czepiel, A., Sikora- Frac, M., & Ceremuzynski, L. (1996). Intravenous amiodarone is safe and seems to be effective in termination of paroxysmal supraventricular tachyarrhythmias. Clinical Cardiology, 19, 563-566.
6. Levine, J. H., Massumi, A., Scheinman, M. M., Winkle, R. A., Platia, E. V., Chilson, D. A., et al. (1996). Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias. Intravenous Amiodarone Multicenter Trial Group. Journal of the American College of Cardiology, 27, 67-75.
7. Kowey, P. R., Levine, J. H., Herre, J. M., Pacifico, A., Lindsay, B. D., Plumb, V. J., et al. (1995). Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. The Intravenous Amiodarone Multicenter Investigators Group. Circulation, 92, 3255-3263.
8. Kosinski, E. J., Albin, J. B., Young, E., Lewis, S. M., & Leland, O. S., Jr. (1984). Hemodynamic effects of intravenous amiodarone. Journal of the American College of Cardiology, 4, 565-570.
9. Kowey, P. R., Marinchak, R. A., Rials, S. J., & Filart, R. A. (1997). Intravenous amiodarone. Journal of the American College of Cardiology, 29, 1190-1198.
10. Abraxis Pharmaceutical Products (2008). Amiodarone hydrochloride injection-Prescribing information. Schaumburg, IL: Abraxis Pharmaceutical Products.
11. Kessler, D., Palepu, N., Tustian, A., Rockwell, K., Leo, A., Hughes, M. P., & Guthrie, R. (2002). A novel amiodarone microemulsion injectable formulation [abstract]. AAPS PharmSci. 4:W4122.
12. Somberg, J. C., Bailin, S. J., Haffajee, C. I., Paladino, W. P., Kerin, N. Z., Bridges, D., et al. (2002). Intravenous lidocaine versus intravenous amiodarone (in a new aqueous formulation) for incessant ventricular tachycardia. American Journal of Cardiology, 90, 853-859.
13. Kipp, J. E, Doty, M. J, Rebbeck, C. L, Eilert, J. Y. (2002). Inventors; Baxter International, assignee. Amiodarone-containing parenteral administration. US patent 6,479,541. 12 November 2002.
14. Elhasi, S., Astaneh, R., & Lavasanifar, A. (2007). Solubilization of an amphiphilic drug by poly(ethylene oxide)-block-poly(ester) micelles. European Journal of Pharmaceutics and Biopharmaceutics, 65, 406-413.
15. Cushing, D. J., Kowey, P. R., Cooper, W. D., Massey, B. W., Gralinski, M. R., & Lipicky, R. J. (2009). PM101: A cyclodextrin- based intravenous formulation of amiodarone devoid of adverse hemodynamic effects. European Journal of Pharmacology, 607, 167-172.
16. Masini, E., Planchenault, J., Pezziardi, F., Gautier, P., & Gagnol, J. P. (1985). Histamine-releasing properties of Polysorbate 80 in vitro and in vivo: Correlation with its hypotensive action in the dog. Agents Actions, 16, 470-477.